Edition:
United States

Axovant Sciences Ltd (AXON.OQ)

AXON.OQ on NASDAQ Stock Exchange Global Select Market

2.42USD
23 Jul 2018
Change (% chg)

$-0.04 (-1.63%)
Prev Close
$2.46
Open
$2.47
Day's High
$2.47
Day's Low
$2.41
Volume
26,595
Avg. Vol
785,018
52-wk High
$27.93
52-wk Low
$1.02

Summary

Name Age Since Current Position

Vivek Ramaswamy

31 2018 Chairman of the Board

Pavan Cheruvu

36 2018 Chief Executive Officer

Gregory Weinhoff

46 2015 Chief Financial Officer

Mark Altmeyer

56 President of Axovant Sciences GmbH and Chief Commercial Officer

Eric Floyd

2017 Senior Vice President - Regulatory Affairs

Ilise Lombardo

2015 Senior Vice President - Clinical Research

Thomas Templeman

2017 Senior Vice President - Pharmaceutical Operations and Quality Assurance

Mark Wadley

2017 Senior Vice President, US Business

Samina Bari

2017 Vice President - Corporate Communications

Shankar Ramaswamy

2015 Vice President - Global Medical Affairs

Stephen Mohr

57 2017 General Counsel

George Bickerstaff

62 2018 Director

Roger Jeffs

56 2018 Director

Berndt Modig

58 2015 Director

Ilan Oren

34 2018 Director

Atul Pande

62 2015 Director

Biographies

Name Description

Vivek Ramaswamy

Mr. Vivek Ramaswamy is Chairman of the Board of the Company. Mr. Vivek Ramaswamy is founder and Chief Executive Officer of Roivant Sciences, Inc., and the founder and former Chief Executive Officer of Axovant Sciences, Inc. Prior to founding Roivant, Mr. Ramaswamy was a well-known investor in the biotechnology sector. In 2007, he co-founded and served as President of Campus Venture Network, a technology company that was acquired in 2009. He currently serves as Chairman of the Board of Directors of Arbutus Biopharma Corporation and a member of the Board of Directors of Axovant Sciences Ltd., Myovant Sciences Ltd., and Roivant Sciences Ltd. He received an A.B. summa cum laude in biology from Harvard College and a J.D. from Yale Law School.

Pavan Cheruvu

Dr. Pavan Cheruvu is Chief Executive Officer of the Company. He has held roles of increasing responsibility at Roivant Sciences, Inc. and in supporting the Company since October 2015. Dr. Cheruvu completed his residency in internal medicine at Johns Hopkins Hospital and continued his training in a clinical fellowship in cardiovascular medicine at the University of California, San Francisco. Prior to his medical training, Dr. Cheruvu worked as a management consultant at McKinsey & Company from June 2008 through June 2011, where he focused on biopharmaceutical strategy. Dr. Cheruvu received his B.S.E. in Biomedical Engineering, B.S.E. in Electrical Engineering, and A.B. in Chemistry from Duke University, his M.Sc. in Computer Science from Oxford University and his M.D. from Harvard Medical School.

Gregory Weinhoff

Dr. Gregory M. Weinhoff, M.D., serves as Chief Financial Officer of the company. Dr. Weinhoff has served as Chief Financial Officer of Axovant Sciences, Inc. since August 2015. He has more than 20 years of experience in healthcare finance and operations including as a venture capital investor, operating executive and board member with Audit Committee experience. Previously, he was a partner at CHL Medical Partners, where he focused on investments in start-up and early-stage companies across therapeutics, diagnostics, medical devices and healthcare services. He was the founding Chief Executive Officer of Amicus Therapeutics and was subsequently a member of the Audit Committee of the company’s board of directors. Earlier in his career, he was founding President of VaxInnate and President of Resolvyx. He also held positions in the healthcare groups at J.H. Whitney & Co. and Morgan Stanley & Co. He received an MD from Harvard Medical School, an MBA from Harvard Business School (Baker Scholar), and an AB in economics (magna cum laude) from Harvard College.

Mark Altmeyer

Mr. Mark Altmeyer is a President of Axovant Sciences GmbH and Chief Commercial Officer subsidiary of the company. He has served as the President and Chief Commercial Officer of Axovant Sciences, Inc. since March 2015. From February 2009 to December 2014, Mr. Altmeyer served as Chief Executive Officer and President of Otsuka America Pharmaceutical, Inc. Prior to his time at Otsuka, Mr. Altmeyer served in a number of executive leadership roles at Bristol-Myers Squibb, including Senior Vice President, Global Commercialization from 2006 to 2008 and Senior Vice President, Neuroscience Business Unit from 2002 to 2005 during the approval and launch of Abilify, a branded drug used to treat multiple psychiatric conditions, including schizophrenia, depression and bipolar disorder. Mr. Altmeyer currently serves as a director for Contact of Mercer County. Mr. Altmeyer received his B.A. from Middlebury College and his M.B.A. from Harvard Business School.

Eric Floyd

Dr. Eric Floyd, Ph.D., serves as Senior Vice President - Regulatory Affairs of the Company. Dr. Floyd has served as senior vice president, regulatory affairs, for Axovant Sciences, Inc. since June 2017. He has nearly 20 years of regulatory experience within the pharmaceutical industry. Most recently, he was president of compliance services and chief scientific officer at Dohmen Life Science Services, Inc. He was Senior Vice President, US Regulatory Affairs and Clinical Quality Compliance at Lundbeck Inc., Global Vice President of Regulatory Affairs at Hospira, Vice President of Worldwide Regulatory Affairs and Quality Assurance at Cephalon and VP and Global Head of Respiratory, Dermatology, and Tropical Medicines Drug Regulatory Affairs at Novartis and held senior leadership roles at Bristol Myers Squibb, Aventis and Merck Research Laboratories. Dr. Floyd received a Ph.D. from Meharry Medical College, Nashville, an MBA from St. Joseph’s University, Philadelphia, an MS from Tennessee State University, and a BS from the University of Illinois.

Ilise Lombardo

Dr. Ilise Lombardo, M.D., serves as Senior Vice President - Clinical Research of the Company. Dr. Lombardo has served as Senior Vice President, clinical research, at Axovant Sciences. Inc. since April 2015. She has 15 years of experience in the pharmaceutical industry leading clinical development and medical affairs programs across multiple therapeutic areas including neurological and psychiatric disorders. She has successfully managed clinical development, regulatory authority approval and post-marketing activities. She is a trained psychiatrist and previously worked in academic research and clinical practice. Previously, she was Vice President, Clinical Development and Medical Affairs, at FORUM Pharmaceuticals. Earlier in her career, she led multi-therapeutic groups and development teams at Pfizer Inc. Prior to entering the pharmaceutical industry, she was an Assistant Professor of Clinical Research at Columbia University College of Physicians and Surgeons and the New York State Psychiatric Institute. She received an MD from Yale University, an M.Phil. from the University of Cambridge, and an AB from Brown University.

Thomas Templeman

Dr. Thomas Templeman, Ph.D., serves as Senior Vice President - Pharmaceutical Operations and Quality Assurance of the Company. Dr. Templeman has served as Senior Vice President, Pharmaceutical Operations and Quality Assurance, for Axovant Sciences, Inc. since June 2017. He has more than 25 years of experience across various aspects of pharmaceutical operations. He most recently served as Chief Operations Officer at Graybug Vision, and was at Medivation prior to that. He previously held positions of increasing responsibility at Hospira, Inc., Liquidia Technologies, and the Johnson & Johnson companies Centocor Biologics and Ortho Clinical Diagnostics. Dr. Templeman received a PhD from Dartmouth College and a BS from the University of Santa Clara.

Mark Wadley

Mr. Mark Wadley serves as Senior Vice President, US Business of the Company. Mr. Wadley has served as Senior Vice President, US Business, for Axovant Sciences, Inc. since May 2017. He has 24 years of commercial leadership experience across sales, marketing, payer access and commercial operations. Mr. Wadley most recently served as Senior Vice President of Sales at Guardant Health and previously was Vice President Oncology Sales, Organized Customers, and Payer at Medivation. He has also held various roles of increasing responsibility at Amgen, Wyeth BioPharma and Genetics Institute. Mr. Wadley holds a BS from Arizona State University.

Samina Bari

Ms. Samina Bari serves as Vice President - Corporate Communications of the Company. Ms. Bari has served as Vice President, Corporate Communications, for Axovant Sciences, Inc. since May 2017. She has more than 25 years of US and global communications experience in the healthcare and pharmaceutical industries. Most recently, she was Vice President of Corporate Communications at Medivation, and was Senior Vice President of Corporate Communications at Pharmacyclics prior to that. She has also held positions of increasing responsibility at Ikaria, Johnson & Johnson and Pfizer, in addition to having held senior-level positions at several of the world’s leading global communications firms. She began her career at a New York teaching hospital. Ms. Bari holds an MA and BA from New York University.

Shankar Ramaswamy

Dr. Shankar Ramaswamy, M.D., serves as Vice President - Global Medical Affairs of the Company. Dr. Ramaswamy is the vice president of global medical affairs for Axovant Sciences, Inc. and joined the company in March 2015. Dr. Ramaswamy was one of the earliest employees of Axovant and has served the company in multiple roles, including most recently as Vice President, Medical and Scientific Communications. He was also involved in the scientific evaluation of new assets for Axovant. Dr. Ramaswamy holds an AB in Economics from Harvard University and a MD from Brown University.

Stephen Mohr

Mr. Stephen F. Mohr serves as General Counsel of the Company. Mr. Mohr has served as General Counsel of Axovant Sciences, Inc. since June 2017. He has more than 25 years of experience in legal and compliance matters affecting the pharmaceutical industry. Before that, he served in a number of senior roles during a 12-year career at AstraZeneca, including US General Counsel and Deputy General Counsel, North America and Global Compliance Officer. Prior to that, he held roles of increasing responsibility during a 14-year career at Bristol-Myers Squibb, including Vice President and Senior Counsel, US Medicines. Earlier in his career, he specialized in litigation matters at Weiss Dawid Fross Zelnick & Lehrman, PC (now Fross Zelnick Lehrman & Zissu) and Rivkin Leff Sherman & Radler (now Rivkin Radler LLP). Mr. Mohr received a JD from the University of Virginia School of Law and a BA (magna cum laude) from Yale University.

George Bickerstaff

Mr. George W. Bickerstaff III., is Director of the company. He is currently a partner and the managing director of M.M. Dillon & Co., a healthcare and technology investment bank that he co-founded. Previously, he served as Chief Financial Officer of Novartis Pharma AG from 2000 to 2005, held senior financial positions at IMS Health from 1989 to 1997 and held financial positions with Dun & Bradstreet and General Electric. Mr. Bickerstaff received his B.S. in Engineering and his B.A. in Business Administration from Rutgers University. Mr. Bickerstaff currently serves as a member of the boards of directors of the following public companies: Cardax, Inc., CareDx, Inc., Innoviva, Inc. and Inovio Pharmaceuticals, Inc. He also previously served on the board of directors of ARIAD Pharmaceuticals, Inc.

Roger Jeffs

Dr. Roger A. Jeffs Ph.D., is Director of the company. He has over 25 years of experience in the biopharmaceutical industry. He recently served as President and co-Chief Executive Officer of United Therapeutics Corporation from January 2015 to June 2016. Dr. Jeffs joined United Therapeutics in 1998 as director of research, development, and medical and served as its President and Chief Operating Officer from April 2001 to December 2014. He also served as a member of its board of directors from 2001 to 2016. Before joining United Therapeutics, he held positions in clinical development at Amgen, Inc. and Burroughs Wellcome Co. Dr. Jeffs is the co-founder and co-owner of Bull City Select Investments, an investment firm focused on in-licensing and development of early-stage biopharma assets. Dr. Jeffs received his B.A. in Chemistry from Duke University and his Ph.D. in Pharmacology from the University of North Carolina School of Medicine. Dr. Jeffs is a member of the boards of directors of the following public companies: Albireo Pharma, Inc., Axsome Therapeutics, Inc., Dova Pharmaceuticals, Inc. and Sangamo Therapeutics, Inc.

Berndt Modig

Mr. Berndt A.E. Modig is a Director of the company. Since March 2016, Mr. Modig has served as Chief Executive Officer of Pharvaris B.V. He served as Chief Financial Officer of Prosensa Holding N.V., a pharmaceutical company, from March 2010 until its acquisition by BioMarin Pharmaceutical Inc. in January 2015. From October 2003 to November 2008, Mr. Modig was Chief Financial Officer at Jerini AG, a pharmaceutical company, where he directed private financing rounds, its initial public offering in 2005, and its acquisition by Shire plc in 2008. Before that, Mr. Modig served as Chief Financial Officer at Surplex AG from 2001 to 2003 and as Finance Director Europe of U.S.-based Hayward Industrial Products Inc. from 1999 to 2001. In previous positions, Mr. Modig was a partner in the Brussels-based private equity firm Agra Industria from 1994 to 1999 and a Senior Manager in the Financial Services Industry Group of Price Waterhouse LLP in New York from 1991 to 1994. Mr. Modig currently serves as a director and member of the audit committee of Affimed N.V. (NASDAQ:AFMD) and as a director and the chair of the audit committee of Auris Medical Holding AG (NASDAQ:EARS), both publicly held pharmaceutical companies. He also serves on the supervisory board of Kiadis Pharma N.V., a public company whose shares are listed on the Euronext Amsterdam and Euronext Brussels stock exchanges. He also served as a director of Mobile Loyalty plc from 2012 to 2013. Mr. Modig received his bachelor’s degree in business administration, economics and German from the University of Lund, Sweden and his M.B.A. from INSEAD, Fontainebleau, France and is a Certified Public Accountant (inactive). We believe that Mr. Modig’s extensive international experience in finance and operations, private equity, and mergers and acquisitions qualifies him to serve on the Board.

Ilan Oren

Mr. Ilan Oren is Director of the Company. Mr. Oren previously served as a member of the Board of the Company from March 2015 to December 2017. Since September 2011, Mr. Oren has served as Vice President, Business Development at Dexcel Pharma Technologies Ltd., an international pharmaceutical company involved in the development, manufacture and commercialization of pharmaceuticals. Mr. Oren currently serves as a director of RSL and he previously served as a director of Cynapsus Therapeutics Inc., a specialty pharmaceutical company, until its acquisition in 2016. Mr. Oren received his B.A. in Economics from Harvard College. The Company believes that Mr. Oren’s extensive leadership experience and knowledge of the life sciences industry qualify him to serve on the Board.

Atul Pande

Dr. Atul Pande, M.D. serves as a Director of the Company. Dr. Pande has served as a member of the Board since March 2015. He serves as the Chief Medical Officer of PureTech Health. Since April 2014, Dr. Pande has served as President of Verity BioConsulting, a drug development consulting firm, and since December 2014 has served as Chief Medical Officer of Tal Medical, a clinical-stage medical device company. From 2007 to April 2014, Dr. Pande was Senior Vice President and Senior Advisor, Pharmaceutical R&D at GlaxoSmithKline, a pharmaceutical company. He has also held senior roles at Pfizer R&D, Parke-Davis/Warner-Lambert and Lilly Research Laboratories. Dr. Pande is also a non-executive board member of Autifony Therapeutics and of Karuna Pharmaceuticals. He also serves on the Scientific Advisory Boards of Cennerv Pharma and Centrexion Corporation. Dr. Pande completed his research fellowship training in psychiatry at the University of Michigan Medical School and his postgraduate specialty training and psychiatry residency program at Western University. We believe that Dr. Pande’s medical background and significant knowledge of the life sciences industry qualify him to serve on the Board.